Trial Profile
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-3614
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs MK 3614 (Primary)
- Indications Hypertension
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 26 Dec 2009 New trial record